Dyne Therapeutics, Inc. DYN Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $753.1M-15.7% | $893.37M+55.7% | $573.61M+18.3% | $485.04M+2.7% | $472.26M+8.5% | ||
| $219.05M+0.9% | $217.19M-0.5% | $218.28M+9.8% | $198.89M-3.1% | $205.24M-0.8% | ||
| $93.3M+65.3% | $56.44M-1.7% | $57.42M+3.0% | $55.76M+1.0% | $55.22M-29.0% | ||
| $1.02B-9.4% | $1.13B+39.7% | $806.26M+15.5% | $697.95M+1.2% | $689.5M+4.6% | ||
| $23.68M-1.4% | $24.03M+0.2% | $23.97M+322% | $5.68M-1.3% | $5.75M+6.5% | ||
| $19.65M-5.3% | $20.74M-4.9% | $21.82M-4.6% | $22.86M-4.3% | $23.88M-3.0% | ||
| $1.08B-9.0% | $1.19B+36.9% | $867.06M+18.9% | $728.99M+1.1% | $721.07M+4.3% | ||
| $10.78M+33.4% | $8.08M-33.0% | $12.06M-13.9% | $14.02M+99.7% | $7.02M+7.0% | ||
| $29.21M-22.2% | $37.55M-12.2% | $42.75M+90.4% | $22.45M+3.2% | $21.75M-29.5% | ||
| $5.03M+0.8% | $5M-0.9% | $5.04M+0.7% | $5M-2.1% | $5.11M+5.4% | ||
| $51.25M+1.2% | $50.63M-15.4% | $59.85M+44.3% | $41.47M+22.4% | $33.88M-19.8% | ||
| $149.38M— | —— | —— | —— | —— | ||
| $14.27M-6.6% | $15.28M-6.1% | $16.28M-5.7% | $17.26M-5.3% | $18.22M-4.8% | ||
| $214.9M0.0% | $214.83M+22.6% | $175.28M+11.3% | $157.55M+202% | $52.1M-15.1% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $16K0.0% | $16K+14.3% | $14K+27.3% | $11K0.0% | $11K+10.0% | ||
| $2.38B+0.6% | $2.37B+19.9% | $1.98B+13.1% | $1.75B+0.8% | $1.73B+9.8% | ||
| -$1.52B-8.7% | -$1.4B-8.7% | -$1.28B-9.2% | -$1.18B-10.4% | -$1.07B-12.1% | ||
| -$137K-129% | $475K-4.2% | $496K+96.8% | $252K+4.6% | $241K+3,917% | ||
| $865.06M-11.0% | $972.13M+40.5% | $691.78M+21.1% | $571.45M-14.6% | $668.97M+6.2% | ||
| $1.08B-9.0% | $1.19B+36.9% | $867.06M+18.9% | $728.99M+1.1% | $721.07M+4.3% | ||
| $219.05M+0.9% | $217.19M-0.5% | $218.28M+9.8% | $198.89M-3.1% | $205.24M-0.8% | ||
| $19.65M-5.3% | $20.74M-4.9% | $21.82M-4.6% | $22.86M-4.3% | $23.88M-3.0% | ||
| $19.65M-5.3% | $20.74M-4.9% | $21.82M-4.6% | $22.86M-4.3% | $23.88M-3.0% | ||
| $15.59M-0.1% | $15.6M+4.0% | $15.01M+498% | $2.51M+29.1% | $1.94M0.0% | ||
| $19.65M-5.3% | $20.74M-4.9% | $21.82M-4.6% | $22.86M-4.3% | $23.88M-3.0% | ||
| —— | —— | —— | —— | —— | ||
| $29.21M-22.2% | $37.55M-12.2% | $42.75M+90.4% | $22.45M+3.2% | $21.75M-29.5% | ||
| $168.68M-0.3% | $169.2M+40.5% | $120.47M-0.5% | $121.08M+419% | $23.33M-2.7% | ||
| $16K0.0% | $16K+14.3% | $14K+27.3% | $11K0.0% | $11K+10.0% | ||
| —— | $0— | $0— | $0— | $0— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Dyne Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 19.92 — current assets exceed current liabilities.
- Where does Dyne Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Dyne Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.